Focus on human microbiome to fight liver cirrhosis
22 European institutions join forces in MICROB-PREDICT to improve the prevention and treatment of chronic liver disease (cirrhosis). We aim to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis), when such decompensated cirrhosis will progress to acute-on-chronic liver failure (ACLF), and a patient’s individual treatment response. Based on such biomarkers, we strive to develop novel diagnostic tools for earlier and better patient stratification and to establish personalised and effective treatment strategies.
Successful 2nd General Assembly Meeting in Königstein, 22 January 2020
From 20 - 22 January 2020, 71 delegates of the MICROB-PREDICT consortium met in Königstein near Frankfurt a. M., Germany, to discuss the progress and results after the end of the first year of the project. We are happy to conclude that the project is in schedule and the first results come in nicely.More events